Aclaris Therapeutics
(NASDAQ:ACRS)
$1.27
0.01[0.79%]
At close: Mar 28
$1.27
0[0.00%]
After Hours: 7:51PM EDT
Consensus Rating1
Neutral
Highest Price Target1
$0.00
Lowest Price Target1
$0.00
Consensus Price Target1
$9.25

Aclaris Therapeutics Stock (NASDAQ:ACRS), Analyst Ratings, Price Targets, Predictions

Aclaris Therapeutics Inc has a consensus price target of $9.25, established from looking at the 27 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., BTIG, and HC Wainwright & Co. on January 22, 2024, January 11, 2024, and December 29, 2023. With an average price target of $3 between HC Wainwright & Co., BTIG, and HC Wainwright & Co., there's an implied 136.22% upside for Aclaris Therapeutics Inc from these 3 analyst ratings.

Analyst Rating Summary1

Analyst Ratings
Oct 23
3
Nov 23
1
2
Dec 23
1
Jan
2
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
BTIG
Stifel
Cantor Fitzgerald
William Blair

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Aclaris Therapeutics

date
ticker
Buy Now
Company
Current price
Upside/Downside
Analyst Firm
Analyst & % Accurate
Price Target Change
Rating Change
Previous / Current Rating
Get Alert
01/22/2024ACRSBuy Now
Aclaris Therapeutics
$1.27HC Wainwright & Co.
Raghuram Selvaraju
DowngradeBuy → NeutralGet Alert
01/11/2024ACRSBuy Now
Aclaris Therapeutics
$1.27BTIG
Julian Harrison
DowngradeBuy → NeutralGet Alert
12/29/2023ACRSBuy Now
Aclaris Therapeutics
$1.27608.66%HC Wainwright & Co.
Raghuram Selvaraju
→ $9ReiteratesBuy → BuyGet Alert
12/18/2023ACRSBuy Now
Aclaris Therapeutics
$1.27-21.26%Stifel
Alex Thompson
$2 → $1MaintainsHoldGet Alert
11/14/2023ACRSBuy Now
Aclaris Therapeutics
$1.27608.66%HC Wainwright & Co.
Raghuram Selvaraju
$43 → $9MaintainsBuyGet Alert
11/14/2023ACRSBuy Now
Aclaris Therapeutics
$1.27Cantor Fitzgerald
Louise Chen
DowngradeOverweight → NeutralGet Alert
11/13/2023ACRSBuy Now
Aclaris Therapeutics
$1.2757.48%Stifel
Alex Thompson
$20 → $2DowngradeBuy → HoldGet Alert
11/13/2023ACRSBuy Now
Aclaris Therapeutics
$1.27William Blair
Tim Lugo
DowngradeOutperform → Market PerformGet Alert
10/09/2023ACRSBuy Now
Aclaris Therapeutics
$1.272892.13%Cantor Fitzgerald
Louise Chen
→ $38ReiteratesOverweight → OverweightGet Alert
10/04/2023ACRSBuy Now
Aclaris Therapeutics
$1.273285.83%HC Wainwright & Co.
Raghuram Selvaraju
→ $43ReiteratesBuy → BuyGet Alert
10/03/2023ACRSBuy Now
Aclaris Therapeutics
$1.271632.28%Evercore ISI Group
Gavin Clark-Gartner
→ $22Initiates → OutperformGet Alert
09/19/2023ACRSBuy Now
Aclaris Therapeutics
$1.272892.13%Cantor Fitzgerald
Louise Chen
→ $38ReiteratesOverweight → OverweightGet Alert
09/19/2023ACRSBuy Now
Aclaris Therapeutics
$1.273285.83%HC Wainwright & Co.
Raghuram Selvaraju
→ $43ReiteratesBuy → BuyGet Alert
09/14/2023ACRSBuy Now
Aclaris Therapeutics
$1.271474.8%Stifel
Alex Thompson
$16 → $20MaintainsBuyGet Alert
08/08/2023ACRSBuy Now
Aclaris Therapeutics
$1.273285.83%HC Wainwright & Co.
Raghuram Selvaraju
→ $43ReiteratesBuy → BuyGet Alert
06/14/2023ACRSBuy Now
Aclaris Therapeutics
$1.273285.83%HC Wainwright & Co.
Raghuram Selvaraju
→ $43ReiteratesBuy → BuyGet Alert
03/07/2023ACRSBuy Now
Aclaris Therapeutics
$1.271553.54%Goldman Sachs
Corinne Jenkins
$25 → $21MaintainsBuyGet Alert
03/07/2023ACRSBuy Now
Aclaris Therapeutics
$1.272183.46%BTIG
Julian Harrison
$32 → $29MaintainsBuyGet Alert
03/07/2023ACRSBuy Now
Aclaris Therapeutics
$1.273285.83%HC Wainwright & Co.
Raghuram Selvaraju
$50 → $43MaintainsBuyGet Alert

FAQ

Q

What is the target price for Aclaris Therapeutics (ACRS)?

A

The latest price target for Aclaris Therapeutics (NASDAQ: ACRS) was reported by HC Wainwright & Co. on January 22, 2024. The analyst firm set a price target for $0.00 expecting ACRS to fall to within 12 months (a possible -100.00% downside). 16 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Aclaris Therapeutics (ACRS)?

A

The latest analyst rating for Aclaris Therapeutics (NASDAQ: ACRS) was provided by HC Wainwright & Co., and Aclaris Therapeutics downgraded their neutral rating.

Q

When was the last upgrade for Aclaris Therapeutics (ACRS)?

A

There is no last upgrade for Aclaris Therapeutics.

Q

When was the last downgrade for Aclaris Therapeutics (ACRS)?

A

The last downgrade for Aclaris Therapeutics Inc happened on January 22, 2024 when HC Wainwright & Co. changed their price target from N/A to N/A for Aclaris Therapeutics Inc.

Q

When is the next analyst rating going to be posted or updated for Aclaris Therapeutics (ACRS)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aclaris Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aclaris Therapeutics was filed on January 22, 2024 so you should expect the next rating to be made available sometime around January 22, 2025.

Q

Is the Analyst Rating Aclaris Therapeutics (ACRS) correct?

A

While ratings are subjective and will change, the latest Aclaris Therapeutics (ACRS) rating was a downgraded with a price target of $0.00 to $0.00. The current price Aclaris Therapeutics (ACRS) is trading at is $1.27, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch